31st Mar 2016 12:20
LONDON (Alliance News) - AstraZeneca PLC on Thursday said the American College of Cardiology and American Heart Association have released treatment guidelines showed a preference for the UK drugmaker's Brilinta over clopidogrel for treating acute coronary syndrome.
The update, covering patients with acute coronary syndrome who have received a coronary stent, is the first time the two organisations have recommended Brilinta over clopidogrel, which is marketed by Bristol-Myers Squibb Co and Sanofi SA.
"We are pleased that the ACC/AHA have further recognised the role of Brilinta across a broad spectrum of ACS. This update reflects the clinical confidence in Brilinta as a treatment option for heart attack patients in the acute setting and in the longer-term," said Elisabeth Bjork, vice-president and head of cardiovascular and metabolic diseases in AstraZeneca's global medicines development division.
AstraZeneca shares were down 0.2% to 3,906.5 pence.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca